• William E Dager, Jeff H King, Ron C Regalia, Dean Williamson, Robert C Gosselin, Richard H White, R Steven Tharratt, and Timothy E Albertson.
• Department of Pharmaceutical Services, University of California, Davis Medical Center, Sacramento, California 95817-2201, USA. william.dager@ucdmc.ucdavis.edu
• Pharmacotherapy. 2006 Aug 1;26(8):1091-8.

Study ObjectiveTo assess the effectiveness of using low-dose recombinant activated factor VII (rFVIIa) to reverse the effects of warfarin in critically ill patients with major bleeding events.DesignProspective observational study.SettingIntensive care unit of a 500-bed university-affiliated hospital.PatientsSixteen nonhemophiliac patients who had been receiving warfarin and had an acute major bleeding event.InterventionPatients received rFVIIa 1.2 mg for reversal of anticoagulation.Measurements And Main ResultsPatients were identified from clinical pharmacology consult service electronic tracking records, and their data were cross-checked with the pharmacy information system. Information collected for each patient included extent of bleeding and magnitude of elevation in international normalized ratio (INR). A mean +/- SD dose of rFVIIa 16.3 +/- 4.1 microg/kg (range 11-25 microg/kg) reduced the mean INR from 2.8 +/- 1.6 (range 1.44-6.34) to 1.07 +/- 0.27 (range 0.86-1.92, p<0.001). A rapid onset of response for achieving a desirable hemostatic effect was observed in 14 of the 16 patients.ConclusionLow-dose rFVIIa appears to be an effective, rapid reversal modality for major bleeding events in the presence of warfarin and an elevated INR. The agent's response is quicker than that expected with fresh frozen plasma combined with vitamin K. In emergency situations, rFVIIa 1.2 mg can be used to reverse the anticoagulant effect of warfarin and other vitamin K antagonists without inducing a hypercoagulable state; the product, however, is expensive.

27 keywords...

hide…